FDA Revokes Emergency Kidney Drugs as COVID Era Fades
Published Date: 5/21/2025
Notice
Summary
The FDA has officially ended the emergency use permissions for certain kidney treatment products from Fresenius and Baxter as of January 16, 2025. This means these products can no longer be used under emergency rules, affecting hospitals and patients relying on them during COVID-19. The change helps ensure only fully approved treatments are used, with no extra costs announced.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Emergency Use Authorizations Revoked
On January 16, 2025, the FDA revoked the Emergency Use Authorizations for Fresenius Medical Care North America’s multiFiltrate PRO System and multiBic/multiPlus solutions (EUA 048) and Baxter Healthcare Corp.’s REGIOCIT (EUA 068). This means those products can no longer be used under emergency rules and the change affects hospitals and patients who were relying on them during the COVID-19 pandemic; the notice also states the change helps ensure only fully approved treatments are used and that no extra costs were announced.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in